(CercleFinance.com) – A new study has shown the link between Covid-19 infection and the activation of the HERV-W protein in a cohort of hospitalized psychotic patients, the biopharmaceutical laboratory GeNeuro announced on Monday.
In an article published in the scientific journal Translational Psychiatry (Nature group), GeNeuro indicates that a Covid infection, even unnoticed or asymptomatic, in psychotic patients, can have an influence on the activation of the endogenous human retrovirus HERV-W in a context of innate immune inflammation.
According to the laboratory, this study highlights the possibility of developing new therapeutic methods and approaches for the treatment of psychotic patients for whom the HERV-W ENV protein is activated.
These results argue, according to him, in favor of a precision medicine strategy targeting this HERV-W protein in these patients presenting post-infectious and immuno-inflammatory profiles.
For the record, the group has initiated a program with temelimab, an antibody directed against HERV-W ENV, for patients presenting persistent neuropsychiatric symptoms following long Covid.
It also launched, at the end of 2022, a phase 2 trial, which evaluates the clinical effectiveness of a six-month treatment with temelimab on the improvement of cognitive disorders and/or fatigue in patients with long Covid. and positive for W-ENV protein in the blood.
Results from the clinical trial are expected in the second quarter of 2024.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Are you following this action?
Receive all the information on GENEURO in real time: